December 15, 2017 10:22 AM ET

Biotechnology

Company Overview of Tyrogenex, Inc.

Company Overview

Tyrogenex, Inc., a biopharmaceutical company, develops targeted cancer therapeutics. The company specializes in developing dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitors for wet age-related macular degeneration (wet AMD) and solid tumors. It offers X-82 that inhibits VEGFR and PDGFR and targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis, and inflammation. The company’s X-82 is used in wet AMD, renal cell carcinoma, pancreatic neuroendocrine tumors, and advanced solid tumors. Tyrogenex, Inc. was formerly known as Xcovery, Inc. The company was incorporated in 2006 and is based in Ro...

155 Gibbs Street

Suite 427

Rockville, MD 20850

United States

Founded in 2006

Phone:

301-880-9595

Fax:

301-880-9599

Key Executives for Tyrogenex, Inc.

President & Chief Executive Officer
Age: 56
Co Founder and Chairman of the Board
Co Founder & Director
Acting Senior Vice President of Drug Development
Director
Age: 58
Compensation as of Fiscal Year 2017.

Tyrogenex, Inc. Key Developments

Tyrogenex Completes Patient Enrollment in Phase 2 Trial of Orally Administered Vorolanib for Wet Age-Related Macular Degeneration

Tyrogenex announced the completion of patient enrollment in the APEX Study – a phase 2 trial of X-82 (vorolanib) for the oral treatment of wet age-related macular degeneration (wAMD). The APEX study is a randomized, double-masked, placebo-controlled, dose-finding, non-inferiority study of X-82 plus as-needed intravitreal anti-VEGF compared to as-needed intravitreal anti-VEGF alone in patients with neovascular AMD. Subjects are being treated for a total of 52 weeks with one of three doses of X-82 or placebo (ClinicalTrials.gov # NCT02348359).

Tyrogenex, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:15 PM

Tyrogenex, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:15 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States. Speakers: Michael D. Webb, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 25, 2017
Equinox Science, LLC
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tyrogenex, Inc., please visit www.tyrogenex.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.